Cargando…

Abstract 58: Favourable outcomes with therapeutic glucocorticoid regimen compared to replacement glucocorticoid regimen in primary hypophysitis

Background: Primary hypophysitis (PH) is most commonly treated with glucocorticoids. But there is considerable variation in the treatment regimens. Aims and Objectives: We aimed to compare the outcomes of therapeutic versus replacement glucocorticoid regimens in PH. Therapeutic regimen (TR) comprise...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Liza, Agrawal, Kanhaiya, Dutta, Pinaki, Gupta1, Kirti, Ahuja2, Chirag Kamal, Singh2, Paramjeet, Tripathi3, Manjul, Sahoo3, Sushant Kumar, Sood4, Ashwani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067731/
http://dx.doi.org/10.4103/2230-8210.342175
_version_ 1784700070503907328
author Das, Liza
Agrawal, Kanhaiya
Dutta, Pinaki
Gupta1, Kirti
Ahuja2, Chirag Kamal
Singh2, Paramjeet
Tripathi3, Manjul
Sahoo3, Sushant Kumar
Sood4, Ashwani
author_facet Das, Liza
Agrawal, Kanhaiya
Dutta, Pinaki
Gupta1, Kirti
Ahuja2, Chirag Kamal
Singh2, Paramjeet
Tripathi3, Manjul
Sahoo3, Sushant Kumar
Sood4, Ashwani
author_sort Das, Liza
collection PubMed
description Background: Primary hypophysitis (PH) is most commonly treated with glucocorticoids. But there is considerable variation in the treatment regimens. Aims and Objectives: We aimed to compare the outcomes of therapeutic versus replacement glucocorticoid regimens in PH. Therapeutic regimen (TR) comprised oral prednisolone (1mg/kg/d) for 6-12 weeks followed by tapering. Replacement regimen (RR) comprised standard hydrocortisone. Response was defined as complete recovery of all pituitary axes, without any requirement of hormonal replacement. Results: Mean age of the cohort (n=30) was 37.8 ± 10.4 years with a female preponderance (79.3%). Response to glucocorticoids was present in 23.3% of the cohort, all on TR. There was no difference between responders and non-responders in terms of age, gender, duration of symptoms or follow-up (p>0.05). Headache was more frequent in responders than non-responders (100% vs 57.1%, p<0.05). Secondary hypocortisolism (100% vs 71.4%), hypothyroidism (71.4% vs 52.4%), hypogonadism (71.4% vs 42.8%), hyposomatotropism (57.1% vs 25%) and hyperprolactinemia (85.7 vs 57.1%) were more common among responders (p<0.05). Diabetes insipidus was not different (42.3% vs 38%, p=0.56). Pituitary enlargement (100% vs 76.2%) and absent posterior pituitary bright spot (PPBS) (71.4% vs 57.1%) were more frequent among responders (p<0.05). Asymmetric enlargement was more common in non-responders (23.8% vs 0, p<0.05). Stalk thickening (80.9% vs 85.7%) and T2 parasellar dark intensity (28.5% each) were not different (p>0.05). The mass regressed in 85.7% in responders and 57.1% of non-responders at a mean follow-up duration of 4.6 ± 2.7 years. Conclusion: Response in PH is optimal with TR. Multiple hormone deficiencies, hyperprolactinemia, symmetric pituitary enlargement and absent PPBS portend favourable response, whereas asymmetric pituitary enlargement is more common among non-responders.
format Online
Article
Text
id pubmed-9067731
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-90677312022-05-05 Abstract 58: Favourable outcomes with therapeutic glucocorticoid regimen compared to replacement glucocorticoid regimen in primary hypophysitis Das, Liza Agrawal, Kanhaiya Dutta, Pinaki Gupta1, Kirti Ahuja2, Chirag Kamal Singh2, Paramjeet Tripathi3, Manjul Sahoo3, Sushant Kumar Sood4, Ashwani Indian J Endocrinol Metab Abstracts … Esicon 2021 Background: Primary hypophysitis (PH) is most commonly treated with glucocorticoids. But there is considerable variation in the treatment regimens. Aims and Objectives: We aimed to compare the outcomes of therapeutic versus replacement glucocorticoid regimens in PH. Therapeutic regimen (TR) comprised oral prednisolone (1mg/kg/d) for 6-12 weeks followed by tapering. Replacement regimen (RR) comprised standard hydrocortisone. Response was defined as complete recovery of all pituitary axes, without any requirement of hormonal replacement. Results: Mean age of the cohort (n=30) was 37.8 ± 10.4 years with a female preponderance (79.3%). Response to glucocorticoids was present in 23.3% of the cohort, all on TR. There was no difference between responders and non-responders in terms of age, gender, duration of symptoms or follow-up (p>0.05). Headache was more frequent in responders than non-responders (100% vs 57.1%, p<0.05). Secondary hypocortisolism (100% vs 71.4%), hypothyroidism (71.4% vs 52.4%), hypogonadism (71.4% vs 42.8%), hyposomatotropism (57.1% vs 25%) and hyperprolactinemia (85.7 vs 57.1%) were more common among responders (p<0.05). Diabetes insipidus was not different (42.3% vs 38%, p=0.56). Pituitary enlargement (100% vs 76.2%) and absent posterior pituitary bright spot (PPBS) (71.4% vs 57.1%) were more frequent among responders (p<0.05). Asymmetric enlargement was more common in non-responders (23.8% vs 0, p<0.05). Stalk thickening (80.9% vs 85.7%) and T2 parasellar dark intensity (28.5% each) were not different (p>0.05). The mass regressed in 85.7% in responders and 57.1% of non-responders at a mean follow-up duration of 4.6 ± 2.7 years. Conclusion: Response in PH is optimal with TR. Multiple hormone deficiencies, hyperprolactinemia, symmetric pituitary enlargement and absent PPBS portend favourable response, whereas asymmetric pituitary enlargement is more common among non-responders. Wolters Kluwer - Medknow 2022-03 /pmc/articles/PMC9067731/ http://dx.doi.org/10.4103/2230-8210.342175 Text en Copyright: © 2022 Indian Journal of Endocrinology and Metabolism https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Abstracts … Esicon 2021
Das, Liza
Agrawal, Kanhaiya
Dutta, Pinaki
Gupta1, Kirti
Ahuja2, Chirag Kamal
Singh2, Paramjeet
Tripathi3, Manjul
Sahoo3, Sushant Kumar
Sood4, Ashwani
Abstract 58: Favourable outcomes with therapeutic glucocorticoid regimen compared to replacement glucocorticoid regimen in primary hypophysitis
title Abstract 58: Favourable outcomes with therapeutic glucocorticoid regimen compared to replacement glucocorticoid regimen in primary hypophysitis
title_full Abstract 58: Favourable outcomes with therapeutic glucocorticoid regimen compared to replacement glucocorticoid regimen in primary hypophysitis
title_fullStr Abstract 58: Favourable outcomes with therapeutic glucocorticoid regimen compared to replacement glucocorticoid regimen in primary hypophysitis
title_full_unstemmed Abstract 58: Favourable outcomes with therapeutic glucocorticoid regimen compared to replacement glucocorticoid regimen in primary hypophysitis
title_short Abstract 58: Favourable outcomes with therapeutic glucocorticoid regimen compared to replacement glucocorticoid regimen in primary hypophysitis
title_sort abstract 58: favourable outcomes with therapeutic glucocorticoid regimen compared to replacement glucocorticoid regimen in primary hypophysitis
topic Abstracts … Esicon 2021
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067731/
http://dx.doi.org/10.4103/2230-8210.342175
work_keys_str_mv AT dasliza abstract58favourableoutcomeswiththerapeuticglucocorticoidregimencomparedtoreplacementglucocorticoidregimeninprimaryhypophysitis
AT agrawalkanhaiya abstract58favourableoutcomeswiththerapeuticglucocorticoidregimencomparedtoreplacementglucocorticoidregimeninprimaryhypophysitis
AT duttapinaki abstract58favourableoutcomeswiththerapeuticglucocorticoidregimencomparedtoreplacementglucocorticoidregimeninprimaryhypophysitis
AT gupta1kirti abstract58favourableoutcomeswiththerapeuticglucocorticoidregimencomparedtoreplacementglucocorticoidregimeninprimaryhypophysitis
AT ahuja2chiragkamal abstract58favourableoutcomeswiththerapeuticglucocorticoidregimencomparedtoreplacementglucocorticoidregimeninprimaryhypophysitis
AT singh2paramjeet abstract58favourableoutcomeswiththerapeuticglucocorticoidregimencomparedtoreplacementglucocorticoidregimeninprimaryhypophysitis
AT tripathi3manjul abstract58favourableoutcomeswiththerapeuticglucocorticoidregimencomparedtoreplacementglucocorticoidregimeninprimaryhypophysitis
AT sahoo3sushantkumar abstract58favourableoutcomeswiththerapeuticglucocorticoidregimencomparedtoreplacementglucocorticoidregimeninprimaryhypophysitis
AT sood4ashwani abstract58favourableoutcomeswiththerapeuticglucocorticoidregimencomparedtoreplacementglucocorticoidregimeninprimaryhypophysitis